The average P/S ratio for MRNA's competitors is 8.95, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -35.33%, this premium appears unsustainable.